Why Ariad Pharmaceuticals, Inc. Shares Vaulted Higher

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Ariad Pharmaceuticals (NASDAQ: ARIA  ) , a biopharmaceutical company focused on developing therapies to treat cancer, vaulted higher by as much as 16% after a report from Reuters noted that Ariad's second-largest shareholder was seeking two board seats.

So what: According to the report, Sarissa Capital Management, which is Ariad's second-largest shareholder with a 6.2% stake in the company, is seeking at least two seats on the company's board of directors. Ariad's board is made up of eight members, of which three are due for reelection in June, however nominations must be received by Feb. 20. Neither Sarissa Capital nor Ariad provided a comment to Reuters concerning the matter.

Now what: Today's hype is really about the potential for an activist investors to step in and do what's needed to improve shareholder value. Sarissa Capital Management is run by Alex Denner, who at one time was Carl Icahn's right-hand man when it came to health-care investments, so he understands a thing or two about being an activist investor and unlocking shareholder value. Despite the news, I would take today's gains with a grain of salt as the company's only FDA-approved drug Iclusig has a long road of recovery left ahead of it after a worrisome two-year follow-up safety study, and is currently only a last resort treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Ariad has roared out of the gate this year, but it'll probably be hard-pressed to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 07, 2014, at 3:29 PM, lolzz wrote:

    i love how these bums love to get in that last jab at ariad.

  • Report this Comment On February 07, 2014, at 11:51 PM, demonroach wrote:

    So basically, we are weeks away from knowing whether Sarissa can nominate anyone, then we are many months away from a board vote...I see a sharp drop next week when people realize not of this news is short term.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2829236, ~/Articles/ArticleHandler.aspx, 8/22/2014 11:35:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement